-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
Viridian Therapeutics, Inc.\DE quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2013 to 2024.
- Viridian Therapeutics, Inc.\DE Net Income (Loss) Attributable to Parent for the quarter ending December 31, 2024 was -$79.7M, a 19.2% decline year-over-year.
- Viridian Therapeutics, Inc.\DE Net Income (Loss) Attributable to Parent for the twelve months ending December 31, 2024 was -$270M, a 13.6% decline year-over-year.
- Viridian Therapeutics, Inc.\DE annual Net Income (Loss) Attributable to Parent for 2024 was -$270M, a 13.6% decline from 2023.
- Viridian Therapeutics, Inc.\DE annual Net Income (Loss) Attributable to Parent for 2023 was -$238M, a 83.1% decline from 2022.
- Viridian Therapeutics, Inc.\DE annual Net Income (Loss) Attributable to Parent for 2022 was -$130M, a 63.5% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)